

Supplementary Material. Table S1. Patients' demographic and baseline characteristics.

Patients' descriptors	Patients who received TIXA/CILGA (n = 106)	Patients who did not received TIXA/CILGA (n = 696)
Male	72	414
Female	34	282
Average age	60 years (range, 20-82)	56 years (range, 20 to 85 years)
Mean time after transplantation	9 years (range, 1 months to 25 years)	10 years (range, 1 month to 38 years)
Serum creatinine concentration ($\mu\text{mol/L}$)	147 (range, 63-808)	122 (range, 50-958)
Estimated GFR (mL/min/1,73 m ²)	51 (4 to 90)	59 (5 to 90)
Immunosuppression regimen		
Calcineurin inhibitor+MA	56%	52%
Calcineurin inhibitor+MA+MP	18%	25%
Calcineurin inhibitor+everolimus	8%	8%
Other combinations	18%	15%
Vaccination against COVID-19		
5 times	1%	0%
4 times	16%	8%
3 times	64%	52%
2 times	18%	22%
Once	0%	2%
No vaccination	1%	16%
Recovered from COVID-19		
3 times	2%	1%
2 times	8%	8%
Once	45%	52%
Never	45%	39%

Legend: TIXA/CILGA- tixagevimab/cilgavimab; GFR – glomerular filtration rate; MA- mycophenolic acid; MP- methylprednisolone.